Lv1
16 积分 2025-12-15 加入
STAGE II NON-SMALL CELL LUNG CANCER: UPFRONT SURGERY OR NEOADJUVANT CHEMOIMMUNOTHERAPY
1个月前
已完结
Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy
1个月前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non–Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations
1个月前
已完结
Foundation model-enhanced multimodal survival prediction in glioblastoma across multi-institutional cohorts
1个月前
已完结
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE)
5个月前
已完结
The paradox of response and survival in cancer therapeutics
9个月前
已关闭
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
9个月前
已完结
Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer—Long-Term Results of a Randomized Clinical Trial
9个月前
已完结
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
9个月前
已完结
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both
9个月前
已完结